RNA test tailors chemo for pancreatic cancer patients

NCT ID NCT04683315

First seen Jan 11, 2026 · Last updated May 08, 2026 · Updated 15 times

Summary

This study tests whether using a tumor's RNA profile (PurIST test) to choose chemotherapy before surgery improves outcomes for people with pancreatic cancer that can be removed. About 84 adults with resectable or borderline resectable disease will receive 12 weeks of personalized treatment. The goal is to see if this approach leads to better tumor shrinkage compared to standard care.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Froedtert & the Medical College of Wisconsin

    RECRUITING

    Milwaukee, Wisconsin, 53226, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • HonorHealth Medical Group

    RECRUITING

    Scottsdale, Arizona, 85258-4566, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-••••

Conditions

Explore the condition pages connected to this study.